The Centers for Disease Control and Prevention (CDC) has adopted new vaccine recommendations that expand protection for respiratory syncytial virus (RSV) and meningococcal disease, backing products ...

The government’s top vaccine official working under Health Secretary Robert F. Kennedy Jr. recently restricted the approval ...

Pfizer (PFE) closed at $25.32 in the latest trading session, marking a +1.12% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.48% for the day. Elsewhere, the Dow ...

Shares of Pfizer Inc. PFE rose 1.12% to $25.32 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.47% to 6,227.42 and the Dow ...

Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company ...

A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that there was a conspiracy among ...

While Pfizer's revenue and earnings did experience a sharp decline following the normalization of COVID-19 product demand, the company's 2025 guidance suggests stabilization is at hand.

Pfizer's dividend payout ratio of 122.5% looks concerning at first glance. A company can only pay out more in dividends than it generates in earnings for a limited time.

Pfizer (NYSE:PFE) is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years. Shares are down 19% over ...